sacubitril/valsartan and frailty in hfpef in paragon-hf | esc congress 2022
Published 1 year ago • 2.4K plays • Length 2:42Download video MP4
Download video MP3
Similar videos
-
5:52
esc 2022: perspective: sacubitril/valsartan & cognitive function in hfmref & hfpef
-
3:33
lbct dapagliflozin by nt-probnp in hfmref or hfpef | esc congress 2022
-
4:23
sacubitril/valsartan combo delivers in acute heart failure
-
7:03
esc 2022: 3 trials that will change your practice with preventive cardiologist, dr martha gulati
-
54:59
double jeopardy: coronary disease in patients undergoing tavi - europcr 2022
-
7:39
day 2 highlights | tct 2022
-
7:42
hfsa 2022: prove-hf: effect of sacubitril/valsartan in hfref pts with mr | dr james l januzzi
-
7:57
hfa 2020: eligibility for sacubitril/valsartan in hf across the ef spectrum — dr gianluigi savarese
-
9:01
entresto/ vymada - sacubitril valsartan - how it protect heart? how it works?
-
10:07
day 1 highlights | esc congress 2022
-
15:02
day 2 highlights | esc congress 2022
-
8:03
day 4 highlights | esc congress 2022
-
3:35
teer for atrial secondary mr | esc congress 2022
-
2:52
lbct recent hf hospitalization in deliver | esc congress 2022
-
2:28
lbct dapagliflozin and atrial fibrillation in hfpef in deliver | esc congress 2022
-
38:43
acc cardiology hour from aha 2022
-
26:17
sacubitril/valsartan: should we reshuffle the deck in the treatment of hf?
-
13:47
chf mortality reduction: ivabradine and sacubitril-valsartan
-
1:10:40
acc cardiology hour from esc congress 2022
-
10:06
renal outcomes of sacubitril/valsartan (arni) in landmark trials